IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of kidney failure. Multiple new therapies are now being evaluated in randomized clinical trials globally. However, most individual trials are not powered to assess treatment effects in key patient subgroups or reliably evalute effects on clinical kidney outcomes. There is a pressing need for coordinated international collaboration that can deliver reliable evidence on the efficacy and safety of emerging therapies across the heterogeneous spectrum of IgAN.
 
 
CLARITY-IgAN addresses this need through meta-analysis of data from major randomized controlled trials in IgAN. The Consortium aims to generate reliable estimates of the effects of various therapeutic classes on kidney, quality-of-life, and safety outcomes; understand how treatment effects vary across demographic, clinical, and histopathologic subgroups; better understand variations in the natural history of IgAN and longitudinal trajectories of proteinuria and eGFR; and develop and validate novel endpoints to enable more efficient future trials.
 
 
Together, these efforts aim to inform clinical practice guidelines, support regulatory science, and ultimately improve care for people living with IgAN worldwide.